First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This is a first-in-human study of a new drug called AZD9793, designed to target a protein called GPC3 that is found on certain cancer cells. It is being tested in people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have spread or cannot be removed surgically. **You may be eligible if...** - You are 18 or older - Your tumor tests positive for the GPC3 protein - You have advanced, recurrent, or metastatic liver cancer (HCC) or another solid tumor - Your cancer has at least one measurable lesion on imaging - You are in reasonably good health and able to carry out daily activities (ECOG 0-1) - Your organs (liver, kidneys, bone marrow) are functioning adequately - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - Your tumor does not express GPC3 - You have severe organ dysfunction - You are pregnant or not using adequate contraception Talk to your doctor to see if this trial is right for you.